$NRSN News

HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8

NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval

NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy Endpoint

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

NeuroSense Therapeutics Announces Data From Its Phase 2 RoAD Trial Of PrimeC In Alzheimer's Disease Demonstrates Multiple Protein Biomarker Changes; Distinctive Changes Also Seen In Levels Of Other Major Neurodegenerative Disease Misfolding Proteins

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Therapeutics Secures Japanese Patent 7857044 Covering Its Lead Drug Candidate For Treatment Of Amyotrophic Lateral Sclerosis

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib'

Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout